New compound inhibits the spread of human prostate, breast and pancreatic cancer in mice
The death of her mother from ovarian cancer when Sui Huang, MD, PhD, was only 12 led to her lifelong scientific pursuit and a new discovery that Huang, an associate professor of Cell and Molecular Biology, hopes may eventually prevent other children from suffering such a painful loss.
In a study published in Science Translational Medicine, Huang and colleagues have used a new approach and discovered a new compound that halts the spread of cancer cells, which is what makes the disease so lethal.
Scientists from the National Cancer Institute (NCI), the University of Kansas, the National Center for Advancing Translational Science (NCAT) and Chen Wang, a research associate in Huang’s lab, worked closely as a team to make this discovery possible.
Huang had already discovered the complex marker that indicates cancer cells’ ability to transform into metastasizing “multiple-headed monsters,” as she describes them.
In the new study, co-corresponding author Huang and colleagues found a compound that blows up the monster and significantly reduced metastasis by human prostate, pancreatic and breast cancer transplanted into mice.
Mice treated with the compound, named metarrestin, had fewer metastatic tumors in the lung and liver, and lived longer than mice that did not receive treatment.
Metarrestin will be submitted to the Food and Drug Administration for approval as an investigational drug in the near future, with the goal of launching a clinical trial.
There currently is not a drug aimed at selectively preventing cancer metastasis.
“It’s like a dirty bomb against cancer,” said Huang, also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, describing metarrestin’s potency against metastasizing cells. “It could potentially result in a better outcome for patients with solid tumor cancers with high potential to spread to other organs. It’s promising.”
Why is it important to develop a drug that doesn’t just target one gene but multiple factors?
“The metastatic cancer cell is a beast that is nearly entirely different from a normal cell,” said Huang, who has been working on this research for 25 years. “Targeting one thing is not sufficient to stop metastatic cancer.”
Most of the time the primary cancer tumor — which can be dealt with by surgery, radiation and chemotherapy — doesn’t cause death.
“What kills people is when cancer spreads to other organs, such as when breast cancer spreads to the brain, liver, lungs or bones,” Huang said.
The cancer patient survival rate has significantly improved in the last 20 years due to earlier diagnosis and combinational treatments. But the survival of people with metastatic cancer has not changed much.
Metarrestin potentially could be effective as part of combinational therapy after cancer surgery.
“This represents a new strategy for developing anti-cancer drugs,” Huang said. “It’s seeking one compound that can potentially affect multiple relevant targets that are promoting metastasis.”
The marker for metastasis Huang and another scientist discovered in the late 1990s is the complex marker PNC, short for perinucleolar compartment. Its presence in the primary tumor correlates to the tumor’s ability to spread and the poor survival of the patients. The higher the PNC level, the worse the prognosis.
Going for total annihilation
For this new study, National Cancer Institute scientists tested 140,000 compounds against PNC, searching for one that caused total annihilation. They finally found a compound and made a large modification to make a more effective one. The new compound, which they named metarrestin, significantly inhibited metastasis in human breast cancer, prostate cancer and pancreatic cancer that had been grafted into mice.
“We wanted to find that magic compound that strikes multiple parts of the monster. It doesn’t just hit its head. It hits its claws, its fangs and its tail,” Huang said.
Scientists inoculated cancer cell lines originally derived from human pancreatic cancer and prostate cancer into mice organs to generate tissue grafts, called xenografts. These mice were then treated with metarrestin and controls.
With breast cancer, the lung pleural fluid was collected and metastatic cells were isolated and directly inoculated into mice without going through the culture system. This type of tissue graft, called patient-derived xenograft, is considered more representative of a human cancer condition.
The physician becomes a scientist
While Huang’s mother’s death inspired her to go into medicine, it was an encounter with an 18-year-old boy during her oncology rotation at a Chinese hospital that drove her to become a scientist.
“He was supposed to be the best student in his hometown,” Huang said. “He had just taken a college entrance exam and got the top score, but he had a high fever.”
He was quickly diagnosed with acute lymphoma. There was little Huang or anyone could do. He died in less than a month.
“I felt so useless,” Huang said. “After that, I felt being a physician wouldn’t help someone like him. I decided to go to graduate school to become a scientist to try to solve the problem.”
Other Northwestern authors are Ali Shilatifard, PhD, the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, Irawati Kandela, PhD, research assistant professor in the Center for Developmental Therapeutics and of Pharmacology, Marzena Lewandowska, PhD, John Norton, PhD, Yiping Wen, Charles Long, Ojus Khanolkar, Warren Chen, Jinsol Kang, Helen Huang, Eric Chow, Esthermanya Goldberg, Coral Feldman, Romi Xi, Deqing Hu, and Andrew Mazar, PhD.
The study was funded by the National Center for Advancing Translational Sciences and NCI through their intramural programs, the National Human Genome Research Institute grant U54HG005031, the National Institute of General Medical Sciences grants R01GM078555 and R01GM0115710, NCI grant 2 P30 CA060553-19, the V Foundation, a donation from the Baskes family to the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the Robert H. Lurie Comprehensive Cancer Center — Translational Bridge Program Fellowship in Lymphoma Research and the Molecular Libraries Initiative funding to the University of Kansas Specialized Chemistry Center.
